Treasury Bldg.
Dublin, Ireland
+353-1-709-4000
http://www.elan.com
Elan has brain and nerve conditions on its mind. The biotech company is focused on the development and sale of pharmaceuticals for neurological and autoimmune disorders. Elan's pipeline of potential future releases includes new drugs for the treatment of neurological conditions such as bipolar disorder and Alzheimer's. Elan's fortunes relied largely on its bestselling multiple sclerosis (MS) and Crohn's disease therapy Tysabri, a monoclonal antibody (single-source protein) therapy it co-developed with